These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

312 related items for PubMed ID: 22183929

  • 1. Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped.
    Rispens T, Vennegoor A, Wolbink GJ, Polman CH, Killestein J.
    Mult Scler; 2012 Jun; 18(6):899-901. PubMed ID: 22183929
    [Abstract] [Full Text] [Related]

  • 2. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C.
    N Engl J Med; 2012 May 17; 366(20):1870-80. PubMed ID: 22591293
    [Abstract] [Full Text] [Related]

  • 3. Deaths and disability from natalizumab are no longer tolerable: Yes.
    Duquette P.
    Mult Scler; 2012 Aug 17; 18(8):1068-9. PubMed ID: 22807470
    [No Abstract] [Full Text] [Related]

  • 4. Deaths and disability from natalizumab are no longer tolerable: No - (they can be avoided).
    Sørensen PS.
    Mult Scler; 2012 Aug 17; 18(8):1070-2. PubMed ID: 22807471
    [No Abstract] [Full Text] [Related]

  • 5. Early onset of natalizumab-related progressive multifocal leukoencephalopathy.
    Damasceno A, von Glehn F, Martinez AR, Longhini AL, Deus-Silva L, Brandão CO, Santos LM, Damasceno BP.
    Mult Scler; 2011 Nov 17; 17(11):1397-8. PubMed ID: 21900356
    [No Abstract] [Full Text] [Related]

  • 6. [Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy].
    Soilu-Hänninen M, Päivärinta M, Sonninen P, Parkkola R, Vuorinen T, Erälinna JP.
    Duodecim; 2013 Nov 17; 129(7):765-70. PubMed ID: 23720945
    [Abstract] [Full Text] [Related]

  • 7. Natalizumab for relapsing-remitting multiple sclerosis.
    Horga A, Tintoré M.
    Neurologia; 2011 Nov 17; 26(6):357-68. PubMed ID: 21193250
    [Abstract] [Full Text] [Related]

  • 8. Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy.
    Vennegoor A, Rispens T, Van Oosten BW, Wattjes MP, Wondergem MJ, Teunissen CE, Van der Kleij D, Uitdehaag BM, Polman CH, Killestein J.
    Mult Scler; 2015 Apr 17; 21(4):481-4. PubMed ID: 25078275
    [Abstract] [Full Text] [Related]

  • 9. Clinical and radiological disease reactivation after cessation of long-term therapy with natalizumab.
    Baumgartner A, Stich O, Rauer S.
    Int J Neurosci; 2012 Jan 17; 122(1):35-9. PubMed ID: 21913869
    [Abstract] [Full Text] [Related]

  • 10. Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision.
    Tur C, Tintoré M, Vidal-Jordana A, Castilló J, Galán I, Río J, Arrambide G, Comabella M, Arévalo MJ, Horno R, Vicente MJ, Caminero A, Nos C, Sastre-Garriga J, Montalban X.
    Mult Scler; 2012 Aug 17; 18(8):1193-6. PubMed ID: 22383232
    [Abstract] [Full Text] [Related]

  • 11. Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosis.
    Dorsey ER, Thompson JP, Noyes K, Dick AW, Holloway RG, Schwid SR.
    Neurology; 2007 May 01; 68(18):1524-8. PubMed ID: 17470756
    [Abstract] [Full Text] [Related]

  • 12. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis.
    Holmén C, Piehl F, Hillert J, Fogdell-Hahn A, Lundkvist M, Karlberg E, Nilsson P, Dahle C, Feltelius N, Svenningsson A, Lycke J, Olsson T.
    Mult Scler; 2011 Jun 01; 17(6):708-19. PubMed ID: 21228027
    [Abstract] [Full Text] [Related]

  • 13. The effect of plasma exchange on serum anti-JC virus antibodies.
    Subramanyam M, Plavina T, Khatri BO, Fox RJ, Goelz SE.
    Mult Scler; 2013 Jun 01; 19(7):912-9. PubMed ID: 23232602
    [Abstract] [Full Text] [Related]

  • 14. Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?
    Maillart E, Louapre C, Lubetzki C, Papeix C.
    Mult Scler; 2014 Apr 01; 20(4):505-9. PubMed ID: 24367037
    [Abstract] [Full Text] [Related]

  • 15. Natalizumab for multiple sclerosis: appraising risk versus benefit, a seemingly demanding tango.
    Gupta S, Weinstock-Guttman B.
    Expert Opin Biol Ther; 2014 Jan 01; 14(1):115-26. PubMed ID: 24289270
    [Abstract] [Full Text] [Related]

  • 16. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
    Bartt RE.
    Curr Opin Neurol; 2006 Aug 01; 19(4):341-9. PubMed ID: 16914971
    [Abstract] [Full Text] [Related]

  • 17. Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis.
    Warnke C, Mausberg AK, Stettner M, Dehmel T, Nekrich L, Meyer zu Horste G, Hartung HP, Fogdell-Hahn A, Adams O, Kieseier BC.
    Neurology; 2013 Oct 15; 81(16):1400-8. PubMed ID: 24049136
    [Abstract] [Full Text] [Related]

  • 18. Multiple sclerosis, natalizumab, and PML: helping patients decide.
    Rudick RA.
    Cleve Clin J Med; 2011 Nov 15; 78 Suppl 2():S18-23. PubMed ID: 22123928
    [Abstract] [Full Text] [Related]

  • 19. CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus.
    Warnke C, Smolianov V, Dehmel T, Andrée M, Hengel H, Zohren F, Arendt G, Wiendl H, Haas R, Hartung HP, Adams O, Kieseier BC.
    Mult Scler; 2011 Feb 15; 17(2):151-6. PubMed ID: 21078695
    [Abstract] [Full Text] [Related]

  • 20. Natalizumab-associated progressive multifocal leukoencephalopathy is not preceded by elevated drug concentrations.
    van Kempen ZL, Leurs CE, Vennegoor A, Wattjes MP, Rispens T, Uitdehaag BM, Killestein J.
    Mult Scler; 2017 Jun 15; 23(7):995-999. PubMed ID: 28112019
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.